You are here

SU11248 Demonstrates Early Efficacy, Safety; Placebo Patients To Switch Immediately to Drug Therapy

NEW YORK, February 8, 2005 -- Pfizer Inc said today that a Phase III study of SU11248, a cancer medicine being developed to treat Gleevec® -resistant gastrointestinal stromal tumor (GIST), has demonstrated efficacy and safety seven months ahead of schedule. Because of these positive results, an independent panel of experts has recommended stopping the trial. Patients who have received placebo are being given the option of switching to SU11248.

SU11248 is a novel, oral multi-targeted cancer therapy that combines anti-angiogenic and anti-tumor activity to simultaneously stop the blood supply to and directly attack tumor cells.

“We are encouraged by this interim data analysis and believe this is a positive step towards establishing SU11248 as an option for patients with Gleevec-resistant GIST,” said Dr. Joseph Feczko, Pfizer president of worldwide development. “Pfizer and study investigators are working together to provide SU11248 to those enrolled in the study as quickly as possible and hope this unique therapy will continue to provide meaningful clinical benefit for cancer patients.”

SU11248 also is being studied in Phase III trials as a potential treatment for renal cell carcinoma.

Source: Pfizer, Inc.

Recent Headlines

Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Vitamin E Found in Samples Around the Country
Study Links Them to Premature Death
Nag With Texting and a ‘Winners Circle’
How Serotonin and Fluoxetine Affect Microbiota Residing in the Gut